Quality-of-life outcomes from a randomized phase III trial of dose-dense weekly paclitaxel and carboplatin compared with conventional paclitaxel and carboplatin as a first-line treatment for stage II-IV ovarian cancer: Japanese Gynecologic Oncology Group trial (JGOG3016)

Annals of Oncology

Volumn 25, Issue 1, 2014, Pages 251-257

  Harano, K ^a   Terauchi, F ^b   Katsumata, N ^a   Takahashi, F ^c   Yasuda, M ^d   Takakura, S ^d   Takano, M ^e   Yamamoto, Y ^f   Sugiyama, T ^g  

^a NIPPON MEDICAL SCHOOL MUSASHI KOSUGI HOSPITAL   (Japan)

^b TOKYO MEDICAL UNIVERSITY   (Japan)

^c KITASATO UNIVERSITY   (Japan)

^d JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^f TOHO UNIVERSITY OHASHI MEDICAL CENTER   (Japan)

^g IWATE MEDICAL UNIVERSITY   (Japan)

Author keywords

Carboplatin; Neurotoxicity; Ovarian cancer; Paclitaxel; Quality of life

Indexed keywords

CARBOPLATIN; PACLITAXEL;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CLINICAL EFFECTIVENESS; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DOSE DENSIFICATION; DRUG DOSE COMPARISON; FEMALE; FUNCTIONAL ASSESSMENT OF CANCER THERAPY GENERAL; FUNCTIONAL ASSESSMENT OF CANCER THERAPY OVARY SUBSCALE; FUNCTIONAL ASSESSMENT OF CANCER THERAPY TAXANE SUBSCALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MEDICATION THERAPY MANAGEMENT; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OUTCOME ASSESSMENT; OVARY CANCER; OVERALL SURVIVAL; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

CARBOPLATIN; NEUROTOXICITY; OVARIAN CANCER; PACLITAXEL; QUALITY OF LIFE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, CYSTIC, MUCINOUS, AND SEROUS; OVARIAN NEOPLASMS; PACLITAXEL; QUALITY OF LIFE; QUESTIONNAIRES; TREATMENT OUTCOME;

EID: 84897387238     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt527     Document Type: Article

References (16)

1. Jemal A, Bray F, Center MM et al. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Bookman MA, Brady MF, McGuire WP et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. J Clin Oncol 2009; 27: 1419-1425.
3. du Bois A, Weber B, Rochon J et al. Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens. J Clin Oncol 2006; 24: 1127-1135.
4. Burger RA, Brady MF, Bookman MA et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011; 365: 2473-2483.
5. Perren TJ, Swart AM, Pfisterer J et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011; 365: 2484-2496.
6. Cohn DE, Kim KH, Resnick KE et al. At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis. J Clin Oncol 2011; 29: 1247-1251.
7. Katsumata N, Yasuda M, Takahashi F et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet 2009; 374: 1331-1338.
8. Katsumata N, Yasuda M, Isonishi S et al. Long-term follow-up of a randomized trial comparing conventional paclitaxel and carboplatin with dose-dense weekly paclitaxel and carboplatin in women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: JGOG3016 trial. J Clin Oncol 2012; 30(suppl), abstr 5003.
9. Cella DF, Tulsky DS, Gray G et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 1993; 11: 570-579.
10. Cella D, Peterman A, Hudgens S et al. Measuring the side effects of taxane therapy in oncology: the functional assessment of cancer therapy-taxane (FACTtaxane). Cancer 2003; 98: 822-831.
11. Basen-Engquist K, Bodurka-Bevers D, Fitzgerald MA et al. Reliability and validity of the functional assessment of cancer therapy-ovarian. J Clin Oncol 2001; 19: 1809-1817.
12. Geert Verbeke GM. Linear Mixed Models for Longitudinal Data. New York: Springer, 2000.
13. Lee JJ, Swain SM. Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol 2006; 24: 1633-1642.
14. Nabholtz JM, Gelmon K, Bontenbal M et al. Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 1996; 14: 1858-1867.
15. Seidman AD, Berry D, Cirrincione C et al. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol 2008; 26: 1642-1649.
16. Sparano JA, Wang M, Martino S et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 2008; 358: 1663-1671.